Pfizer -Walk-In Drive For Multiple Openings in Manufacturing Function On 18th Feb’ 2023
Pharma Pathway
FEBRUARY 14, 2023
Candidates from OSD and Injectibels can attend interview.
64 
Pfizer -Walk-In Drive For Multiple Openings in Manufacturing Function On 19th Feb’ 2023
Pharma Pathway
FEBRUARY 14, 2023
Candidates from OSD and Injectibels can attend interview.
Join 11,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
FDA approves Novo Nordisk’s Wegovy for cardiovascular risk reduction
Pharmaceutical Business Review
MARCH 11, 2024
This label expansion follows a supplemental New Drug Application (sNDA) submitted by the company. Additionally, the updated label for Wegovy includes findings demonstrating a 15% decline in cardiovascular mortality and a 19% reduction in mortality from any cause, both versus placebo.
Blood Sugar, Hashimoto’s, Ozempic, Metformin and Berberine
The Thyroid Pharmacist
NOVEMBER 15, 2024
Ozempic is a GLP-1 agonist and is actually marketed as a diabetes drug, but many physicians are prescribing it for weight loss (off label-use). Ozempic’s label warns, “In studies with rodents, Ozempic® and medicines that work like Ozempic® caused thyroid tumors, including thyroid cancer.
Let's personalize your content